Education
About Us
Working with TipRanks
Follow Us
aTyr Pharma (ATYR)
NASDAQ:ATYR
Top Page
aTyr Pharma
(NASDAQ:ATYR)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.88
▲(8.02% Upside)
Action:ReiteratedDate:03/06/26
The score is held down primarily by weak financial performance—shrinking revenue, widening losses, and heavy ongoing cash burn that increases financing/dilution risk. Technical indicators are neutral-to-mixed and do not offset the longer-term downtrend, while valuation is limited by negative earnings and no dividend support.
Positive Factors
Strong Equity Position
A strong equity position provides aTyr Pharma with a solid financial foundation, offering resilience against financial volatility and supporting long-term strategic investments.
Proprietary Platform
aTyr Pharma's proprietary platform offers a competitive edge in developing innovative therapies, potentially leading to breakthrough treatments and sustainable revenue streams.
Manageable Debt Levels
Low debt levels reduce financial risk and interest burden, allowing aTyr Pharma to focus resources on R&D and strategic growth initiatives.
Negative Factors
Declining Revenue
Declining revenue highlights challenges in product adoption or market penetration, potentially impacting long-term growth and financial sustainability.
Negative Cash Flow
Negative cash flow indicates operational inefficiencies and may limit aTyr Pharma's ability to fund new projects or withstand economic downturns, posing long-term financial risks.
Nasdaq Deficiency Notice
The Nasdaq deficiency notice poses a risk of delisting, which could limit access to capital markets and negatively impact investor confidence and stock liquidity.
aTyr Pharma (ATYR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$79.25M
Dividend YieldN/A
Average Volume (3M)1.35M
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue Growth-19.15%
EPS Growth10.90%
CountryUS
Employees56
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.14
Shares Outstanding98,051,210
10 Day Avg. Volume1,041,496
30 Day Avg. Volume1,345,055
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.08
Price to Sales (P/S)383.25
P/FCF Ratio-1.17
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue423.92
Enterprise Value/Gross Profit-3.61
Enterprise Value/Ebitda-1.07
Forecast
1Y Price Target
$7.33Price Target Upside804.94% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.58
Revenue Forecast (FY)$3.85M
aTyr Pharma Business Overview & Revenue Model
Company DescriptionaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
How the Company Makes MoneyaTyr Pharma generates revenue primarily through the development and commercialization of its therapeutic products. The company may receive funding from grants, collaborations, and partnerships with larger pharmaceutical entities that provide financial support in exchange for rights to develop and market certain products. Additionally, aTyr can earn revenue through milestone payments associated with the successful advancement of its drug candidates through clinical trials and regulatory approvals. Another potential revenue stream includes royalties from sales of partnered products, once they are commercialized.
aTyr Pharma Earnings Call Summary
Earnings Call Date:Mar 13, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in clinical trials and market opportunities, along with a solid financial position. However, there are challenges related to limited clinical studies for benchmarking and high unmet medical needs in the current market landscape.Q4-2024 Updates
Positive Updates
Completion of Enrollment in EFZO-FIT Phase 3 Study
aTyr completed enrollment in the global pivotal Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis, enrolling 268 patients across 85 centers in 9 countries.
Positive Safety Profile in Phase 3 Study
Four positive data and safety monitoring board reviews for EFZO-FIT identified no safety concerns, recommending the study to continue unmodified.
Increased Market Opportunity for Efzofitimod
Recent analysis shows the U.S. patient population for sarcoidosis is 30% higher than previously estimated, suggesting a larger market opportunity for efzofitimod.
Publication in Science Translational Medicine
An extensive manuscript on efzofitimod's mechanism of action and preclinical data was published in the journal Science Translational Medicine, validating its immunomodulatory properties.
Strong Financial Position and Cash Runway
aTyr ended 2024 with $75.1 million in cash and raised an additional $18.8 million, with a cash runway expected to fund operations through one year following the Phase 3 EFZO-FIT readout.
Negative Updates
Limited Clinical Studies in Sarcoidosis
There are limited clinical studies in sarcoidosis to benchmark against, presenting challenges in pioneering a path forward for measuring improvements in this patient population.
Potential Market Challenges
Despite potential market opportunities, current treatment practices indicate significant mortality and hospitalization rates, reflecting high unmet medical needs.
Company Guidance
During aTyr Pharma's fourth quarter and full year 2024 conference call, the company provided comprehensive guidance on their clinical developments and strategic outlook. They highlighted the completion of enrollment in the pivotal Phase 3 EFZO-FIT study for efzofitimod, aimed at treating pulmonary sarcoidosis. This trial involves 268 patients across 85 centers in nine countries, testing doses of 3 mg/kg and 5 mg/kg against a placebo over 52 weeks, with a primary endpoint focused on steroid reduction. The company also noted that 75% of diagnosed sarcoidosis patients are prescribed steroids, with the U.S. patient population being 30% larger than previously estimated. Additionally, they have observed four positive data and safety monitoring board reviews with no safety concerns. Financially, aTyr ended 2024 with $75.1 million in cash, supplemented by $18.8 million from an ATM offering. They project their cash runway will last through a year following the Phase 3 readout. The company also discussed plans for commercial readiness and the potential for efzofitimod in a $2-5 billion ILD market, with sarcoidosis representing a significant portion.aTyr Pharma Financial Statement Overview
Summary
Very weak fundamentals: revenue is minimal and declining, losses are large and widening, and operating/free cash flow remain deeply negative—implying ongoing financing needs and dilution risk. The main support is relatively low leverage, which slightly improves flexibility.Income Statement
ATYR is operating with a very small revenue base that has been volatile and trending down since 2022 (from ~$10.4M in 2022 to ~$0.19M in 2025). Profitability remains deeply negative, with losses widening over time (net loss of about -$74.1M in 2025 vs. -$50.4M in 2023), indicating a cost structure far ahead of current commercial scale. While this profile is not unusual for clinical-stage biotech, the lack of meaningful revenue traction and persistent heavy losses weigh on the income statement quality.18
Very Negative
Balance Sheet
The balance sheet shows modest leverage, with debt low relative to equity (debt-to-equity ~0.18 in 2025), which reduces near-term solvency pressure. However, equity and assets have declined versus earlier years (equity down to ~$67.5M in 2025 from ~$90.7M in 2023), consistent with ongoing losses and burn. Returns to shareholders are meaningfully negative (return on equity around -1.10 in 2025), highlighting dilution/balance sheet erosion risk if cash needs persist.56
Neutral
Cash Flow
Cash generation is weak with sustained cash burn: operating cash flow was roughly -$62.0M in 2025 and has been negative every year shown. Free cash flow is similarly negative (about -$62.1M in 2025) and deteriorated versus 2023 (about -$37.4M), suggesting increasing funding needs. Free cash flow tracks net loss closely (roughly 1.0x), implying losses are largely translating into cash outflows rather than being cushioned by non-cash items.22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 190.00K | 235.00K | 353.00K | 10.39M | 0.00 |
| Gross Profit | -1.36M | 235.00K | 353.00K | 8.69M | -1.30M |
| EBITDA | -76.07M | -66.37M | -52.18M | -44.71M | -32.47M |
| Net Income | -74.12M | -64.02M | -50.39M | -45.34M | -33.77M |
Balance Sheet | |||||
| Total Assets | 94.16M | 96.83M | 120.65M | 95.79M | 115.54M |
| Cash, Cash Equivalents and Short-Term Investments | 78.69M | 72.13M | 98.17M | 66.15M | 107.91M |
| Total Debt | 12.03M | 13.28M | 15.10M | 11.53M | 1.38M |
| Total Liabilities | 26.88M | 27.00M | 30.18M | 24.50M | 6.41M |
| Stockholders Equity | 67.48M | 70.02M | 90.66M | 71.46M | 109.30M |
Cash Flow | |||||
| Free Cash Flow | -62.06M | -69.18M | -37.44M | -43.53M | -33.27M |
| Operating Cash Flow | -61.99M | -69.12M | -33.22M | -41.89M | -33.08M |
| Investing Cash Flow | -5.05M | 17.23M | -20.13M | 47.24M | -91.57M |
| Financing Cash Flow | 66.01M | 39.86M | 66.23M | 5.45M | 110.03M |
aTyr Pharma Technical Analysis
Negative
0.81
Price Trends
0.86
Negative
0.82
Negative
2.42
Negative
Market Momentum
-0.02
Positive
41.41
Neutral
12.39
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATYR, the sentiment is Negative. The current price of 0.81 is below the 20-day moving average (MA) of 0.92, below the 50-day MA of 0.86, and below the 200-day MA of 2.42, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 41.41 is Neutral, neither overbought nor oversold. The STOCH value of 12.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATYR.
aTyr Pharma Risk Analysis
aTyr Pharma disclosed 70 risk factors in its most recent earnings report. aTyr Pharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
aTyr Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $188.38M | -2.24 | -129.98% | ― | 250.00% | 15.15% | |
57 Neutral | $264.61M | ― | -30.93% | ― | ― | 69.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $79.25M | ― | -99.62% | ― | -19.15% | 10.90% | |
42 Neutral | $80.65M | -7.23 | ― | ― | ― | ― |
* Healthcare Sector Average
ATYR
aTyr Pharma
0.81
-2.89
-78.16%
XBIT
XBiotech
2.39
-1.07
-30.92%
PRLD
Prelude Therapeutics
2.99
2.27
315.28%
CNTX
Context Therapeutics
2.88
2.12
278.95%
OKYO
OKYO Pharma Limited Sponsored ADR
1.57
0.15
10.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.